The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Phage Choice, Isolation, and Preparation for Phage Therapy
Abstract
Phage therapy is the use of bacteriophages--viruses that use bacteria as their host cells--as biocontrol agents of bacteria. Currently, phage therapy is garnering renewed interest as bacterial resistance to antibiotics becomes widespread. Historically, phage therapy was largely abandoned in the West in the 1940s due to the advent of chemical antibiotics, and the unreliability of phage-based treatments when compared to antibiotics. The choice of phage strain and the methods of phage preparation are now thought to have been critical to the success or failure of phage therapy trials. Insufficiently virulent phages, especially against actual target bacteria, allow bacteria to survive treatment while poorly prepared phage stocks, even if of sufficiently virulent phages, lack the numbers of viable phages required for adequate treatment. In this review we discuss the factors that determine the methods of isolation, analysis, and identification of phage species for phage therapy. We go on to discuss the various methods available for purifying phages as well as considerations of the degree of purification which is sufficient for various applications. Lastly, we review the current practices used to prepare commercial phage therapy products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lysogenic Conversion by a Filamentous Phage Encoding Cholera Toxin
Waldor, M. K., & Mekalanos, J. J. (1996) · Science · doi:10.1126/science.272.5270.1910 · Cited by 1,879
Ecology of prokaryotic viruses
Weinbauer, M. G. (2004) · FEMS Microbiology Reviews · doi:10.1016/j.femsre.2003.08.001 · Cited by 1,771
Yamamoto, K. R., Alberts, B. M., Benzinger, R., Lawhorne, L., & Treiber, G. (1970) · Virology · doi:10.1016/0042-6822(70)90218-7 · Cited by 1,565
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Self-citationDowd, S. E., Sun, Y., Secor, P. R., Rhoads, D. D., Wolcott, B. M., James, G. A., & Wolcott, R. D. (2008) · BMC Microbiology · doi:10.1186/1471-2180-8-43 · Cited by 784
Phage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Long-circulating bacteriophage as antibacterial agents.
Merril, C. R., Biswas, B., Carlton, R., Jensen, N. C., Creed, G. J., Zullo, S., & Adhya, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3188 · Cited by 512
Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004944 · Cited by 511
Switches in Bacteriophage Lambda Development
Oppenheim, A. B., Kobiler, O., Stavans, J., Court, D. L., & Adhya, S. (2005) · Annual Review of Genetics · doi:10.1146/annurev.genet.39.073003.113656 · Cited by 495
Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A. N., Powell, B., Carlton, R., & Merril, C. R. (2002) · Infection and Immunity · doi:10.1128/iai.70.1.204-210.2002 · Cited by 467
Cited by
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Phage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Phage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Self-citationPhage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy
Malik, D. J., Sokolov, I. J., Vinner, G. K., Mancuso, F., Cinquerrui, S., Vladisavljevic, G. T., Clokie, M. R. J., Garton, N. J., Stapley, A. G. F., & Kirpichnikova, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.05.014 · Cited by 594
Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth
Hyman, P. (2019) · Pharmaceuticals · doi:10.3390/ph12010035 · Cited by 546
Self-citationKhan Mirzaei, M., & Nilsson, A. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118557 · Cited by 516
Bacteriophages as potential new therapeutics to replace or supplement antibiotics
Kutateladze, M., & Adamia, R. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.08.001 · Cited by 483
A metagenomic insight into our gut's microbiome
Lepage, P., Leclerc, M. C., Joossens, M., Mondot, S., Blottière, H. M., Raes, J., Ehrlich, D., & Doré, J. (2013) · Gut · doi:10.1136/gutjnl-2011-301805 · Cited by 370
More Is Better: Selecting for Broad Host Range Bacteriophages
Ross, A., Ward, S., & Hyman, P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01352 · Cited by 367
Self-citationBacteriophage for Biocontrol of Foodborne Pathogens: Calculations and Considerations
Hagens, S., & Loessner, M. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725429 · Cited by 366
Lamichhane, B., Mawad, A. M. M., Saleh, M., Kelley, W. G., Harrington, P. J., Lovestad, C. W., Amezcua, J., Sarhan, M. M., El Zowalaty, M. E., Ramadan, H., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13010076 · Cited by 353
Harper, D., Parracho, H., Walker, J., Sharp, R., Hughes, G., Werthén, M., Lehman, S., & Morales, S. (2014) · Antibiotics · doi:10.3390/antibiotics3030270 · Cited by 342
Rebuilding the Gut Microbiota Ecosystem
Gagliardi, A., Totino, V., Cacciotti, F., Iebba, V., Neroni, B., Bonfiglio, G., Trancassini, M., Passariello, C., Pantanella, F., & Schippa, S. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15081679 · Cited by 340
Phage Therapy in the Food Industry
Endersen, L., O'Mahony, J., Hill, C., Ross, R. P., McAuliffe, O., & Coffey, A. (2014) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-030713-092415 · Cited by 338
The factors affecting effectiveness of treatment in phages therapy
Ly-Chatain, M. H. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00051 · Cited by 331
The Prevalence and Control of Bacillus and Related Spore-Forming Bacteria in the Dairy Industry
Gopal, N., Hill, C., Ross, P. R., Beresford, T. P., Fenelon, M. A., & Cotter, P. D. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01418 · Cited by 316
Revisiting phage therapy: new applications for old resources
Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.01.006 · Cited by 310
Abedon, S., & Thomas-Abedon, C. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725410 · Cited by 284
Standardized bacteriophage purification for personalized phage therapy
Luong, T., Salabarria, A.-C., Edwards, R. A., & Roach, D. R. (2020) · Nature Protocols · doi:10.1038/s41596-020-0346-0 · Cited by 274
Forti, F., Roach, D. R., Cafora, M., Pasini, M. E., Horner, D. S., Fiscarelli, E. V., Rossitto, M., Cariani, L., Briani, F., Debarbieux, L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02573-17 · Cited by 269
The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies
Liu, D., Van Belleghem, J. D., de Vries, C. R., Burgener, E., Chen, Q., Manasherob, R., Aronson, J. R., Amanatullah, D. F., Tamma, P. D., & Suh, G. A. (2021) · Viruses · doi:10.3390/v13071268 · Cited by 268
The Advantages and Challenges of Using Endolysins in a Clinical Setting
Murray, E., Draper, L. A., Ross, R. P., & Hill, C. (2021) · Viruses · doi:10.3390/v13040680 · Cited by 263
Drulis-Kawa, Z., Majkowska-Skrobek, G., Maciejewska, B., Delattre, A.-S., & Lavigne, R. (2012) · Current Protein & Peptide Science · doi:10.2174/138920312804871193 · Cited by 261
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Interaction of phages, bacteria, and the human immune system: Evolutionary changes in phage therapy
Jariah, R. O. A., & Hakim, M. S. (2019) · Reviews in Medical Virology · doi:10.1002/rmv.2055 · Cited by 40
The applications of animal models in phage therapy: An update
Mehmood Khan, F., Manohar, P., Singh Gondil, V., Mehra, N., Kayode Oyejobi, G., Odiwuor, N., Ahmad, T., & Huang, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2175519 · Cited by 32
Mutalik, V. K., & Arkin, A. P. (2022) · iScience · doi:10.1016/j.isci.2022.104121 · Cited by 32
Metadata
- Authors
- Gill, J., & Hyman, P.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 2-14
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2024931582
- Cited by
- 441
- References
- 36
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.